MetaCap

Xenetic Biosciences (XBIO) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XTL Biopharmaceuticals is the larger company by market cap ($3.4 million vs $3.3 million), about 1.0 times the size. Xenetic Biosciences converts more of its revenue into profit, with a net margin of -90.1% versus -227.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

XBIO-36.65%XTLB-30.81%
+4%-17%-39%
Oct 7, 20261 yearNov 20, 2026
XBIO-34.27%XTLB-30.81%
+4%-16%-36%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

XBIO versus XTLB key metrics
MetricXBIOXTLB
Share price$1.40$1.37
Market cap$3.28M$3.37M
1-day change-9.09%-5.84%
EPS (TTM)$-1.55$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.98M$451.00K
Revenue growth (YoY)+19.04%—
Net income (latest FY)$-2.68M$-1.03M
Gross margin—0.67%
Operating margin-95.23%-481.60%
Net margin-90.07%-227.72%
52-week high$4.94$5.64
52-week low$1.25$1.37
Distance from 52-week high-71.65%-75.71%
Average volume73.30K6.58K
Shares outstanding2.34M2.46M
Employees24
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Xenetic Biosciences is more profitable, keeping -90.1 cents of every revenue dollar as net income versus -227.7 cents for XTL Biopharmaceuticals.

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

XBIO vs XTLB FAQ

Which is bigger, Xenetic Biosciences or XTL Biopharmaceuticals?

XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $3.37M compared with $3.28M for Xenetic Biosciences (XBIO).

Are Xenetic Biosciences and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons